Want to see TSE:RX full AI Analyst Report?
Biosyent (RX) Income Statement
Biosyent Income Statement
Last quarter (Q2 2026), Biosyent's total revenue was $19.87M, an increase of 95.23% from the same quarter last year. In Q2, Biosyent's net income was $2.85M. See Biosyent’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 43.05M | $ 35.03M | $ 31.59M | $ 27.93M | $ 28.62M | |
| $ 32.11M | $ 27.86M | $ 25.60M | $ 22.86M | $ 22.64M | |
| $ 20.80M | $ 19.10M | $ 18.13M | $ 15.95M | $ 14.39M | |
| Depreciation and Amortization | $ 852.49K | $ 589.95K | $ 455.34K | $ 451.00K | $ 457.11K |
| $ 12.17M | $ 10.43M | $ 9.06M | $ 7.43M | $ 8.64M | |
| $ 11.31M | $ 8.75M | $ 7.47M | $ 6.98M | $ 8.18M | |
| $ 716.86K | $ 1.03M | $ 1.06M | $ 448.65K | $ 195.22K | |
| $ 12.03M | $ 9.78M | $ 8.53M | $ 7.43M | $ 8.38M | |
| $ 9.01M | $ 7.27M | $ 6.46M | $ 5.46M | $ 6.28M | |
| Per Share Metrics | |||||
| Basic EPS | $ 0.80 | $ 0.63 | $ 0.54 | $ 0.44 | $ 0.50 |
| Diluted EPS | $ 0.78 | $ 0.62 | $ 0.53 | $ 0.44 | $ 0.49 |
| Weighted Average Shares Outstanding | 11.26M | 11.59M | 11.95M | 12.30M | 12.69M |
| Weighted Average Shares Outstanding (Diluted) | 11.51M | 11.81M | 12.17M | 12.54M | 12.87M |
Currency in CAD
